A popular class of diabetes medications called GLP-1R agonists may also protect against glaucoma in people with diabetes.
Researchers from the Scheie Eye Institute at the University of Pennsylvania’s Perelman School of Medicine examined retrospective data of 1,961 people with diabetes new to GLP-1R agonists (Trulicity and Rybelsus) and matched them to 4,371 unexposed control subjects. After 150 days on average, 10 people in the medicated group were newly diagnosed with glaucoma compared to 58 patients in the control group. This suggests that GLP-1 receptor agonists may decrease a person’s risk of developing glaucoma by half.
The findings were published in the British Journal of Ophthalmology. To read the study, CLICK HERE.